San Diego, CA, United States of America

Derek Mendy

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Celgene Corporation. Active years: 2016-2018.

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 32(Granted Patents)


Company Filing History:


Years Active: 2016-2018

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Derek Mendy

Introduction

Derek Mendy is a prominent inventor based in San Diego, CA. He has made significant contributions to the field of medical research, particularly in the treatment of cancer and inflammatory diseases. With a total of 2 patents, Mendy's work is paving the way for advancements in patient care and drug treatment.

Latest Patents

Mendy's latest patents focus on the use of the protein cereblon as a predictor of clinical sensitivity to cancer and inflammatory diseases. His innovative methods aim to enhance patient response to drug treatment, providing a more personalized approach to therapy. These patents represent a crucial step forward in understanding how specific proteins can influence treatment outcomes.

Career Highlights

Derek Mendy is currently employed at Celgene Corporation, where he continues to develop groundbreaking solutions in the medical field. His work at Celgene has allowed him to collaborate with leading experts and contribute to significant advancements in drug development.

Collaborations

Mendy has worked alongside notable colleagues such as Antonia Lopez-Girona and Peter Henry Schafer. Their combined expertise fosters a collaborative environment that enhances the potential for innovative breakthroughs in their research.

Conclusion

Derek Mendy's contributions to the field of medical research are noteworthy and impactful. His innovative patents and collaborative efforts at Celgene Corporation highlight his commitment to improving patient outcomes in the treatment of cancer and inflammatory diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…